MetaCap

Monopar Therapeutics (MNPR) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 119.7% versus a loss of 24.6%. Over five years, MNPR leads with a +184.5% price change compared with -52.0% for STTK. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $454.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MNPR-24.64%STTK+119.70%
+314%+126%-62%
Nov 21, 20251 yearNov 20, 2026
MNPR+192.99%STTK-52.55%
+431%+156%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MNPR versus STTK key metrics
MetricMNPRSTTK
Share price$69.00$4.46
Market cap$467.60M$454.22M
1-day change-1.84%-1.98%
YTD return+5.67%+22.19%
1-year return-24.64%+119.70%
5-year return+184.54%-51.99%
EPS (TTM)$-2.44$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$1.00M
Revenue growth (YoY)—-82.52%
Net income (latest FY)$-13.72M$-48.81M
Operating margin—-5150.80%
Net margin—-4880.90%
52-week high$124.82$8.33
52-week low$50.07$1.93
Distance from 52-week high-44.72%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+88.65%+245.29%
Average volume151.83K1.20M
Shares outstanding6.78M101.84M
Employees2240
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed MNPR by 144.3 percentage points over the past year.

About Monopar Therapeutics

MNPR stock →

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

MNPR vs STTK FAQ

Which is bigger, Monopar Therapeutics or Shattuck Labs?

Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $454.22M for Shattuck Labs (STTK).

Which stock has performed better over the past year, MNPR or STTK?

STTK returned +119.70% over the past 12 months, compared with -24.64% for MNPR (price return, excluding dividends). Past performance does not predict future results.

Are Monopar Therapeutics and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons